Walk in interview for M.Pharm, B.Pharm, M.Sc in Quality Control, Quality Assurance, Production, ADL, R&D at IPCA Lab
IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

The flagship company of the Piramal Group, Piramal Enterprises Ltd. (PEL), has business interests in Pharma, Information Management, and Financial Services verticals of the group. Towards the late 80s, we shifted our focus from textile to pharmaceuticals. We chose to invest significantly in the domestic formulation development business, while other companies in the industry concentrated on international generics. Our efforts proved successful with a track record of approximately 23% revenue CAGR. In 2010, our strategy accomplished a sale of its domestic formulations business at an unprecedented value of ~9x sales and ~30x EBITDA.

